Delivering base editors to the liver and lungs in alpha-1 antitrypsin deficiency

1. Strnad, P., McElvaney, N. G. & Lomas, D. A. Alpha₁-antitrypsin deficiency. N. Engl. J. Med. 382, 1443–1455 (2020). A review article on AATD.

   Article 
   CAS 
   PubMed 
   
   Google Scholar 

2. Zamora, M. R. & Ataya, A. Lung and liver transplantation in patients with alpha-1 antitrypsin deficiency. Ther. Adv. Chronic Dis. 12, (Suppl.) 20406223211002988 (2021). A review article that presents current treatment options for AATD.

3. Stiles, K. M. et al. Intrapleural gene therapy for alpha-1 antitrypsin deficiency-related lung disease. Chronic Obstr. Pulm. Dis. 5, 244–257 (2018). A review article on gene therapy for AATD.

   PubMed 
   PubMed Central 
   
   Google Scholar 

4. Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat. Nanotechnol. 15, 313–320 (2020). This paper reports the LNP SORT methodology.

   Article 
   CAS 
   PubMed 
   PubMed Central 
   
   Google Scholar 

5. Beam Therapeutics. A phase 1/2 dose-exploration and dose-expansion study to evaluate the safety and efficacy of BEAM-302 in adult patients with alpha-1 antitrypsin deficiency (AATD)-associated lung disease and/or liver disease. https://clinicaltrials.gov/study/NCT06389877 (2025). A clinical study that presents base editor AATD treatment.

Download references

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Kim, M. et al. Dual SORT LNPs for multi-organ base editing. Nat. Biotechnol. https://doi.org/10.1038/s41587-025-02675-z (2025).